-+ 0.00%
-+ 0.00%
-+ 0.00%

According to a research report published by UBS, Kangfang Biotech's partner Summit received a full response letter from the US FDA regarding IVONESCIMAB combined with chemotherapy for non-small cell lung cancer after TKI treatment. The bank thought it was slightly negative, but it constituted emotional stress. The bank indicated that the main reason was that a statistically significant end point for overall survival was not reached. The bank estimates peak sales for this indication at 550 million yuan, accounting for only 1% of total overseas sales of evosimab. The bank believes that the main catalyst is still H-3. The number of progression-free survival events in the first-line squamous non-small cell lung cancer cohort is expected to meet the standards in the fourth quarter of 2026. The bank maintained Kangfang Biotech's “buy” rating and target price of HK$149.

Zhitongcaijing·11/16/2026 03:09:02
Listen to the news
According to a research report published by UBS, Kangfang Biotech's partner Summit received a full response letter from the US FDA regarding IVONESCIMAB combined with chemotherapy for non-small cell lung cancer after TKI treatment. The bank thought it was slightly negative, but it constituted emotional stress. The bank indicated that the main reason was that a statistically significant end point for overall survival was not reached. The bank estimates peak sales for this indication at 550 million yuan, accounting for only 1% of total overseas sales of evosimab. The bank believes that the main catalyst is still H-3. The number of progression-free survival events in the first-line squamous non-small cell lung cancer cohort is expected to meet the standards in the fourth quarter of 2026. The bank maintained Kangfang Biotech's “buy” rating and target price of HK$149.